Livagen
Liver bioregulator peptide
Hepatic tissue bioregulator.
Half-life
~ hours
Mol. weight
~ 418.4 g/mol
Sequence
Lys-Glu-Asp-Ala (KEDA)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in hepatic (liver) tissue, with proposed support for liver cell function and hepatic metabolism. The liver is a remarkable regenerator, which makes it a conceptually compatible target for a bioregulator aimed at supporting tissue renewal.
Mechanism of action
Livagen is a bioregulator peptide studied for regulating gene expression in hepatic tissue. The liver is the body's premier regenerating organ — capable of regrowing from a fraction of its mass — so a bioregulator aimed at supporting hepatocyte gene expression is conceptually well-matched. The mechanism follows the Khavinson framework: ultra-short peptide transcriptional modulation in a tissue-specific manner.
Researched benefits
- Studied for liver support
- Targets the body's premier regenerating organ
- Short bioregulator format
Considerations
- Liver disease requires medical care, not self-research
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Livagen in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Livagen:
View Livagen index on PubMed (NCBI)